Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Stroke Patients Who Have Swallowing Problems Less Likely To Develop Chest Infections Thanks To New Technology
Recovering stroke patients and others who find it hard to swallow when they eat and drink are now at a lower risk of developing pneumonia or chest infections, thanks to new technology which will help assess and treat their swallowing difficulties. Many patients suffering from stroke, head injury or major trauma often have swallowing difficulties when food and drink can go down the wrong way - patients can later develop nasty chest infections and pneumonias. Don't forget to buy zoloft online no prescription.

Glucose Metabolism And Recidivism Of Severe Violent Crimes In Alcohol Intoxications
It is commonly known that alcoholism and alcohol intoxications are connected with severe violent crimes such as homicides. For instance, in Finland even 80 per cent of these crimes happen in alcohol intoxications. It has not, however, been clear why only a minority of alcoholics in intoxications become irritated and impulsively aggressive or even commit severe violent crimes.

generic viagra online


News of the day
Xeloda(R)-Oxaliplatin Combination (XELOX) Shown To Be More Effective Than Standard Chemotherapy Regimen In Adjuvant Colon Cancer
Genentech, Inc. announced that an international Phase III study demonstrated that oral Xeloda® plus oxaliplatin (XELOX) is superior to a commonly used intravenous chemotherapy, 5-FU/LV (infused 5-fluorouracil plus leucovorin), in increasing the time people with adjuvant colon cancer lived without their cancer returning when given immediately after surgery. The data show those who participated in the study and took XELOX immediately after surgery lived longer without their cancer being detectable than those who took intravenous 5U/LV. No new adverse events related to Xeloda were observed in the study.
Nutrition

FDA Clears Hologic R2(TM) DigitalNow(TM) HD Software Application

Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced that it has received Food and Drug Administration (FDA) clearance for its R2(TM) DigitalNow(TM) HD software application. The R2 DigitalNow HD software is the only FDA-cleared application intended to process digitized screen-film mammograms for comparison purposes. The product is now available worldwide. By collaborating with radiologists to understand the demands of reading digital mammograms, Hologic created the R2 DigitalNow HD software, which adapts each digitized film image to a selected contrast and tissue intensity that models a digital mammography system. It also embeds a series of look-up tables in the image that allow Integrated Healthcare Enterprise (IHE) mammography conformant workstations to draw out less evident regions of density within digitized films.(1) "The DigitalNow HD software is designed to enhance workflow by promoting consistency in the digital mammography reading environment," said Julian Marshall, director, R2 product management & principal engineer at Hologic. "One of the most powerful capabilities of this product is that images already digitized by R2 DigitalNow software and stored in PACS can be routed to R2 DigitalNow HD and reprocessed." About Hologic, Inc. Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic"s core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. Hologic, DigitalNow, and R2 are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries. All other trademarks and registered trademarks are the property of their respective owners. Forward Looking Statement Disclaimer This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the effect and adoption of the use of the R2 Digital Now system. There can be no assurance that the system will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the R2 Digital Now system can only be determined on a case-by-case basis depending on the particular circumstances of the procedure and patient in question. Thus there can be no assurance of general adoption of this technology by the medical community. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company"s expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company"s business and prospects are described in Hologic filings with the Securities and Exchange Commission. (1) The "IHE Mammo" profile defines the necessary mammography requirements for the display quality, behavior, layout and annotation of prior and current mammography image for diagnostic workstations. Hologic, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009